Sacubitril-valsartan in the treatment of chronic heart failure with decreased left ventricular ejection fraction
Abstract
Increasing incidence of chronic heart failure and its unfavorable prognosis keep calling for novel pharmacotherapeutic approaches. New class of drugs described as ARNI (angiotensin receptor/neprilysin inhibitor) recently widened the spectrum of possibilities how to treat heart failure with decreased left ventricular ejection fraction.
Statistically and clinically significant lowering of cardiovascular mortality and risk of rehospitalization for heart failure was shown in the PARADIGM-HF trial following the treatment with sacubitril-valsartan, so far the only representative of ARNI. The ARNI drugs are indicated in patients with stabilized heart failure NYHA II-III and decreased left ventricular ejection fraction; they can be considered an alternative of the current standard treatment with renin-angiotensin-aldosterone system blockers.